<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525274</url>
  </required_header>
  <id_info>
    <org_study_id>20-7-2020</org_study_id>
    <nct_id>NCT04525274</nct_id>
  </id_info>
  <brief_title>Intraperitoneal Dexmedetomidine Versus Ketamine With Bupivacaine For Postoperative Analgesia</brief_title>
  <official_title>Comparative Study Between Intraperitoneal Dexmedetomidine Versus Ketamine With Bupivacaine For Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-laparoscopic sleeve pain management is essential for early mobilization of the patient&#xD;
      and so on decrease post-operative complication. The use of opioids is associated with adverse&#xD;
      effects such as nausea, pruritus, sedation, and occasionally respiratory depression.&#xD;
&#xD;
      Previous studies stated that intraperitoneal instillation of bupivacaine alone has been used&#xD;
      to reduce acute postoperative abdominal and shoulder pain allow early mobilization and&#xD;
      decrease postoperative opioid requirements and its complications.&#xD;
&#xD;
      In this study the investigators will compare between intraperitoneal instillation of&#xD;
      dexmedetomidine with bupivacaine versus ketamine with bupivacaine in patients undergoing&#xD;
      laparoscopic sleeve gastrectomy under general anesthesia regarding to postoperative pain&#xD;
      relief to reduce morbidity and mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is a serious condition in developed and developing countries occur due to some&#xD;
      hormonal disorder or due to reduce energy expenditure with increasing energy uptake [1].&#xD;
      Nowadays, obesity considered the second cause of deaths after smoking all over the world [2].&#xD;
&#xD;
      Severe obesity increase the incidence of many chronic disease such as (diabetes mellitus,&#xD;
      hypertension, cardiovascular diseases and others) [3]. This leads to substantial morbidity,&#xD;
      early mortality [4], impaired quality of life [5] and excess healthcare expenditures [6].&#xD;
&#xD;
      Laparoscopic bariatric surgery is the most recommended and effective long-term treatment for&#xD;
      morbid obesity (which body mass index (BMI) ≥40 kg/m2) and obesity-related complication [7].&#xD;
&#xD;
      Postoperative pain management after laparoscopic sleeve still considers a major challenge. As&#xD;
      many of the patients express moderate-to-severe pain in postoperative period [8]. Causes of&#xD;
      postoperative pain include inflammation of the peritoneum, intra-abdominal cavity stretch and&#xD;
      irritation of diaphragm by carbon-dioxide (CO2) remains in the abdominal cavity [9].&#xD;
&#xD;
      Multimodal analgesia regimens such as parenteral opioids, nonsteroidal anti-inflammatory&#xD;
      drugs and intraperitoneal instillation of different drugs such as local anesthetic drugs&#xD;
      alone or with adjuvants like; opioid and α2 agonists' drugs such as clonidine and&#xD;
      dexmedetomidine have been tried to reduce overall pain and postoperative complications of&#xD;
      patients undergoing laparoscopic surgeries [8, 9].&#xD;
&#xD;
      Bupivacaine is the most commonly used local anesthetic drug, its intraperitoneal instillation&#xD;
      has become a popular practice for pain relief after laparoscopic surgery as it causes&#xD;
      blockade of free afferent nerve endings in peritoneum [10].&#xD;
&#xD;
      Dexmedetomidine, the pharmacologically active d-isomer of medetomidine, it is a potent and&#xD;
      highly selective α2-adrenoreceptor agonist with sympatholytic, sedative, amnestic,&#xD;
      anxiolytic, neuroprotective and analgesic properties [11].&#xD;
&#xD;
      Ketamine is an immunomodulatory agent and anti-inflammatory drug and it has a noncompetitive&#xD;
      antagonist of the N-methyl-d-aspartate (NMDA) receptor that blocks nociceptive input and&#xD;
      reduce hyperalgesia [12].&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Anticipated">October 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patients will be divided randomly by a computer-generated randomization table into three equal groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>triple blinded (patient, surgeon and outcomes assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>change in assessment of postoperative shoulder, abdominal and incisional pain</measure>
    <time_frame>at 1, 2, 4, 6, 12 and 24 hours postoperatively</time_frame>
    <description>will be assessed by visual analogue scale (VAS) scale, On a scale of 0-10, the patient will learn to quantify postoperative pain where 0= No pain and 10= Maximum worst pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of first request of analgesia</measure>
    <time_frame>within 24 hour postoperative</time_frame>
    <description>time elapsed from patient arrival to PACU [T0] to time of first patient call for analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total rescue analgesic requirement</measure>
    <time_frame>during the first postoperative 24 hours</time_frame>
    <description>if VAS ≥3 or on patient request, rescue analgesia will be given</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of postoperative nausea and vomiting (PONV)</measure>
    <time_frame>during the first postoperative 24 hours</time_frame>
    <description>occurrence of postoperative nausea and vomiting</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient will receive 40 ml bupivacaine 0.25% + 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient will receive 40 ml bupivacaine 0.25% + 1 µg/kg dexmedetomidine diluted in 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketamine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient will receive 40 ml bupivacaine 0.25% + 0.5 mg/kg ketamine diluted in 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of 40 ml bupivacaine 0.25% + 5 ml normal saline will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.&#xD;
The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 1 µg/kg dexmedetomidine diluted in 5 ml normal saline) will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.&#xD;
The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure.</description>
    <arm_group_label>dexmedetomidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 0.5 mg/kg ketamine diluted in 5 ml normal saline) will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.&#xD;
The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure.</description>
    <arm_group_label>ketamine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient acceptance.&#xD;
&#xD;
          -  Age 21-60 years old.&#xD;
&#xD;
          -  Sex both male and female.&#xD;
&#xD;
          -  BMI ≥40 kg/m2&#xD;
&#xD;
          -  ASA II and ASA III.&#xD;
&#xD;
          -  Scheduled for elective laparoscopic sleeve gastrectomy under general anesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known history of allergy to study drugs.&#xD;
&#xD;
          -  Patients with uncontrolled diabetes mellitus.&#xD;
&#xD;
          -  Psychological and mental disorders.&#xD;
&#xD;
          -  Severe hypertensive, cardiac, hepatic and renal patients.&#xD;
&#xD;
          -  Patients on opioid or sedative use.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rehab A Wahdan, MD</last_name>
    <phone>01003481323</phone>
    <phone_ext>002</phone_ext>
    <email>obz13w@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Asmaa M Galal, MD</last_name>
    <phone>01271550089</phone>
    <phone_ext>002</phone_ext>
    <email>asmaa_galal79@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>faculty of medicine, Zagazig university</name>
      <address>
        <city>Zagazig</city>
        <state>Elsharqya</state>
        <zip>44519</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howaida A Kamal, MD</last_name>
      <phone>01225096755</phone>
      <phone_ext>002</phone_ext>
      <email>k.howaida@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Ozkan AS. Anesthesia management in sleeve gastrectomy: Single center experience. Annals of Medical Research. 2018; 25(4)613-8.</citation>
  </results_reference>
  <results_reference>
    <citation>Tekeli AE, Eker E, Bartin MK, Oner MO. Anesthesia Management in Laparoscopic Sleeve Gastrectomy Cases. East J Med. 2019; 24(3): 335-9.</citation>
  </results_reference>
  <results_reference>
    <citation>Praveena BL, Bharathi B, Sahana VR. Intraperitoneal Ropivacaine with Dexmedetomidine or Fentanyl for Postoperative Analgesia Following Laparoscopic Cholecystectomy: A Comparative Randomized Trial. Anesth Essays Res. 2019 Jan-Mar;13(1):169-173. doi: 10.4103/aer.AER_191_18.</citation>
    <PMID>31031500</PMID>
  </results_reference>
  <results_reference>
    <citation>Beder El Baz MM, Farahat TEM. Intraperitoneal Levobupivacaine Alone or with Dexmedetomidine for Postoperative Analgesia after Laparoscopic Cholecystectomy. Anesth Essays Res. 2018 Apr-Jun;12(2):355-358. doi: 10.4103/aer.AER_205_17.</citation>
    <PMID>29962597</PMID>
  </results_reference>
  <results_reference>
    <citation>EL-Gaby SS, Mohammed SS. Intraperitoneal ketamine attenuates the inflammatory reactivity associated with pneumoperitoneum. Research and Opinion in Anesthesia &amp; Intensive Care. 2017; 4:149-55.</citation>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2020</study_first_submitted>
  <study_first_submitted_qc>August 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Rehab Abd-Allah Wahdan</investigator_full_name>
    <investigator_title>lecturer of anesthesia and surgical intensive care</investigator_title>
  </responsible_party>
  <keyword>sleeve gastrectomy</keyword>
  <keyword>postoperative analgesia</keyword>
  <keyword>intraperitoneal dexmedetomidine</keyword>
  <keyword>intraperitoneal ketamine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>planned after the completion of the study and publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>planned after the completion of the study and publication</ipd_time_frame>
    <ipd_access_criteria>principal investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

